Skip to main content

Table 2 Details of adjuvant chemotherapy in the PF group and TPF group

From: Survival outcomes of adjuvant taxanes, platinum plus fluoropyrimidines versus platinum and fluoropyrimidines for gastric cancer patients after D2 gastrectomy: a retrospective propensity score-matched analysis

  PF group [n (%), n = 425] TPF group [n (%), n = 177] X2/Z P
Taxanes     
 Paclitaxel 72 (40.7)
 Docetaxel 105 (59.3)
Fluoropyrimidines     
 5-Fu 118 (27.8) 98 (55.4) 44.493 < 0.001
 Capecitabine 182 (42.8) 37 (20.9)   
 S1 125 (29.4) 42 (23.7)   
Platinum     
 Cisplatin 20 (4.7) 80 (45.2) 158.765 < 0.001
 Oxaliplatin 398 (93.6) 88 (49.7)   
 Lobaplatin 7 (1.6) 9 (5.1)   
Time to chemotherapy after surgery (days) [median (IQR)] 38 (31~47) 37 (31~47) −0.167a 0.867
Duration of adjuvant chemotherapy (days) [median (IQR)] 116 (53~159) 127 (74~175) −1.743a 0.081
Cycles of adjuvant chemotherapy [median (IQR)] 4 (2~6) 4 (3~6) −0.711a 0.477
  1. aIndependent-samples Mann-Whitney U test
  2. PF, platinum plus fluoropyrimidines; TPF, taxanes, platinum plus fluoropyrimidines; IQR, inter quartile range